{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ursprung S"],"funding":["Cancer Research UK","Medical Research Council","NIHR Cambridge Biomedical Research Centre","AstraZeneca","Cancer Research UK Cambridge Centre"],"pagination":["1238"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8600815"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments for later-phase clinical trials. Renal cell carcinoma (RCC), the 7<sup>th</sup> commonest solid cancer in the UK, exhibits targets for multiple new systemic anti-cancer agents including DNA damage response inhibitors, agents targeting vascular pathways and immune checkpoint inhibitors. Here we present the trial protocol for the WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer (WIRE).<h4>Methods</h4>WIRE is a Phase II, multi-arm, multi-centre, non-randomised, proof-of-mechanism (single and combina"],"journal":["BMC cancer"],"pubmed_title":["The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol."],"pmcid":["PMC8600815"],"funding_grant_id":["27176","MR/T024097/1","C9685/A25177","MC_UU_00002/6","27150","BRC-1215-20014"],"pubmed_authors":["Ursprung S","Warren AY","Skells R","Matakidou A","Sala E","Oades G","Sullivan M","Fife K","Young G","Stone J","Mitchell TJ","Sipple JAN","Welsh SJ","Gallagher FA","Ortuzar MC","Eisen T","Walker A","Thomas MG","Protheroe A","Venugopal B","Stewart GD","Wason J","Mossop H","Chhabra A"],"additional_accession":[]},"is_claimable":false,"name":"The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.","description":"<h4>Background</h4>Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments for later-phase clinical trials. Renal cell carcinoma (RCC), the 7<sup>th</sup> commonest solid cancer in the UK, exhibits targets for multiple new systemic anti-cancer agents including DNA damage response inhibitors, agents targeting vascular pathways and immune checkpoint inhibitors. Here we present the trial protocol for the WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer (WIRE).<h4>Methods</h4>WIRE is a Phase II, multi-arm, multi-centre, non-randomised, proof-of-mechanism (single and combina","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-05-08T12:07:36.002Z","creation":"2022-02-11T13:03:47.383Z"},"accession":"S-EPMC8600815","cross_references":{"pubmed":["34794412"],"doi":["10.1186/s12885-021-08965-4"]}}